About Us

Accera is a clinical stage biotechnology company that develops therapies for central nervous system disorders. Accera’s proprietary scientific platform addresses numerous unmet needs in brain health including Alzheimer’s disease. We believe our development-stage proprietary compounds have innovative mechanisms of action that have the potential to positively impact patients’ lives as well as those of their families. Our executive management team includes globally recognized specialists in central nervous system diseases who together leverage the latest scientific knowledge and understanding of neurological disorders.

Accera has developed a marketed product for Alzheimer’s disease and is currently developing a pipeline of innovative products targeting neurodegenerative conditions. Our lead product candidate, AC-1204, a ketosis-inducing compound, is being studied in patients with mild to moderate Alzheimer’s disease.

Management Team

Alzheimer’s disease

  • Alzheimer’s disease (AD) is an age-associated, neurodegenerative disease characterized by a progressive decline in memory and language and pathologically, by accumulation of senile plaques and neurofibrillar tangles in the brain. Despite significant advances in AD research, there exists a tremendous need for new AD therapies. Most developed countries will experience a dramatic demographic shift toward an older population in the next 50 years, which is anticipated to greatly increase the prevalence of AD. The rise in the number of AD patients will place a tremendous social and economic burden on the developed world.

  • Despite being identified over 100 years ago, the cause of Alzheimer’s disease is still not well understood. Unfortunately, drug development for AD has proven to be very difficult, with few successes and many failures. Currently, only 5 drugs are approved for the treatment of AD including 4 cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an N-methyl-D-aspartate (NMDA) receptor antagonist (memantine). No new compounds have been approved for AD since 2003. Tacrine was approved by the US Food and Drug Administration (FDA) in 1993, donepezil in 1996, rivastigmine in 1998, galantamine in 2001, and memantine in 2003. Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a statistically significant difference or having unacceptable toxicity. The failure rate of AD drug development between 2002 and 2012 is 99.6%.1

    1. Cummings, J. L., T. Morstorf, et al. (2014). “Alzheimer’s disease drug-development pipeline: few candidates, frequent failures.” Alzheimers Res Ther 6(4): 37.
  • The lack of new treatments and the repeated failure of pipeline drugs have significantly impacted not only the lives of patients and associated family members, but also the economy at the national level. In 2013, it was calculated that the total cost for dementia care (largely AD) in the US was $215 billion. Further calculations demonstrated that the increasing prevalence of dementia, due to the aging of the US population will result in an increase of nearly 80% in total societal costs by 2040, with total care costs of approximately $511 billion. Therefore, the development of new treatments that delay onset or progression of the disease are desperately needed.2

    2. Hurd, M. D., P. Martorell, et al. (2013). “Monetary costs of dementia in the United States.” N Engl J Med 368(14): 1326-34.


Alzheimer’s disease in Numbers


people with dementia worldwide


dollar world cost in 2015


cause of death in the U.S.


compound since 2003

Board of Directors

Advisory Board

Dr. Michael Weiner

Dr. Weiner has been doing research for over 40 years and is the Principal Investigator of the Alzheimer’s Disease Neuroimaging Initiative, a 10-year, national, longitudinal study of over 1500 subjects which is aimed at validating biomarkers for Alzheimer’s disease. He has also launched BrainHealthRegistry.org which is an internet-based registry with the overall goal of accelerating development of effective treatments for brain diseases. This website registry recruits, screens, and longitudinally monitors brain function on thousands of subjects all over the United States. His overall research goals are to participate in the development of effective treatments and methods for early detection of Alzheimer’s disease and other brain disorders. In 1980, Dr. Weiner was one of the first investigators to use nuclear magnetic resonance to investigate the metabolism of organs inside a living animal. This technique subsequently became magnetic resonance spectroscopy (MRS). In 1988, his group used MRS to show that the amino acid, N-acetylaspartate (NAA), a marker of healthy nerve cells, is reduced in the epileptic focus in the brain. This marker is now used to help identify the epileptic focus prior to surgery in epilepsy patients. In 2004, Dr. Weiner’s group reported that reduced NAA predicts development of Alzheimer’s disease in mildly impaired elderly subjects. They have also demonstrated that brain blood flow is reduced in Alzheimer’s disease and in patients with mild impairment. Dr. Weiner has over 700 published articles. In 2006, Dr. Weiner received the William S. Middleton Award, the highest scientific honor bestowed by the Department of Veterans Affairs. In 2010, he was named one of the “Rock Stars of Science”. He also received the Gold Medal of Paul Sabatier University and the City of Toulouse, France. In 2011, he received the Ronald and Nancy Reagan Research Award from the Alzheimer’s Association. In 2012, he received the Potamkin Award from the American Academy of Neurology and the American Brain Foundation.


  • Alzheimer’s Association
  • INC Research
  • Inventages
  • MS society
  • Nestle Health Science
  • Nestlé Purina Corporate

Latest News


Accera Supports World Alzheimer’s Day

BROOMFIELD, Colo., Sept. 17, 2015 – Accera, Inc., a clinical-stage biotechnology company developing therapies for central nervous system disorders,...

Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease

BROOMFIELD, Colo., July 14, 2015 /PRNewswire/ — Accera, Inc. today announced that it has achieved 75% enrollment for its NOURISH AD Phase 3...

Accera Hoping for an Alzheimer’s Breakthrough

Denver Business Journal Article Accera hoping for an alzheimer’s breakthrough. DISCLAIMER: The views, opinions and information expressed in this...

Accera Pivots From Medical Foods to Potential Drug for Alzheimer’s

The war against Alzheimer’s disease has been a brutal, losing fight. Those stricken with the disease, their loved ones,...